The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response. An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial

JACC: Cardiovascular Interventions

Volumn 1, Issue 6, 2008, Pages 620-627

  Gladding, Patrick ^a   Webster, Mark ^a   Zeng, Irene ^a   Farrell, Helen ^a   Stewart, Jim ^a   Ruygrok, Peter ^a   Ormiston, John ^a   El Jack, Seif ^a   Armstrong, Guy ^a   Kay, Patrick ^a   Scott, Douglas ^a   Gunes, Arzu ^b   Dahl, Marja Liisa ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

antiplatelets; clopidogrel; pharmacogenetics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; PURINERGIC P2Y12 RECEPTOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ELECTIVE SURGERY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INHIBITION KINETICS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; GENE FREQUENCY; GENOTYPE; HUMANS; P-GLYCOPROTEIN; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2; STENTS; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 57549092687     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.09.008     Document Type: Article

References (36)

1. Geiger J., Brich J., Honig-Liedl P., et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 19 (1999) 2007-2011
2. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
3. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
4. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
5. Clarke T.A., and Waskell L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31 (2003) 53-59
6. Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007) 2429-2436
7. Suh J.W., Koo B.K., Zhang S.Y., et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174 (2006) 1715-1722
8. Farid N.A., Payne C.D., Small D.S., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81 (2007) 735-741
9. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
10. Fontana P., Hulot J.S., De Moerloose P., and Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 5 (2007) 2153-2155
11. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
12. Wang A., Yu B.N., Luo C.H., et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60 (2005) 843-848
13. Hesselink D.A., van Schaik R.H., van der Heiden I.P., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245-254
14. Hesselink D.A., van Gelder T., van Schaik R.H., et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 76 (2004) 545-556
15. van Schaik R.H., de Wildt S.N., Brosens R., van Fessem M., van den Anker J.N., and Lindemans J. The CYP3A4*3 allele: is it really rare?. Clin Chem 47 (2001) 1104-1106
16. van Schaik R.H., de Wildt S.N., van Iperen N.M., Uitterlinden A.G., van den Anker J.N., and Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 46 (2000) 1834-1836
17. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26 (2006) 1895-1900
18. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
19. Sim S.C., Risinger C., Dahl M.L., et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79 (2006) 103-113
20. Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007) 2429-2436
21. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
22. Taubert D., von Beckerath N., Grimberg G., et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80 (2006) 486-501
23. Fontana P., Dupont A., Gandrille S., et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108 (2003) 989-995
24. Fontana P., Gaussem P., Aiach M., Fiessinger J.N., Emmerich J., and Reny J.L. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 108 (2003) 2971-2973
25. von Beckerath N., von Beckerath O., Koch W., Eichinger M., Schomig A., and Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 16 (2005) 199-204
26. Tang M., Mukundan M., Yang J., et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319 (2006) 1467-1476
27. Marsh S., Xiao M., Yu J., et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84 (2004) 661-668
28. Gladding P., Webster M., Zeng I., et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Intv 1 (2008) 612-619
29. Luo H.R., Poland R.E., Lin K.M., and Wan Y.J. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 80 (2006) 33-40
30. Kahn J. Race in a bottle. Drugmakers are eager to develop medicines targeted at ethnic groups, but so far they have made poor choices based on unsound science. Sci Am 297 (2007) 40-45
31. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., and Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4 (2006) 2508-2509
32. Gilard M., Arnaud B., Cornily J.-C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
33. Malek L.A., Kisiel B., Spiewak M., et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 72 (2008) 1165-1169
34. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
35. Trenk D., Hochholzer W., Fromm M.F., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51 (2008) 1925-1934
36. Romkes M., Faletto M., Blaisdell J., Raucy J., and Goldstein J. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30 (1991) 3247-3255